Trump's psychedelics executive order: microdosing updates on policy direction, agencies involved, and what it could change

Trump's psychedelics executive order is framed as a policy shift toward faster, more structured handling of psychedelic-related regulation and research. The discussion centers on what the order directs federal agencies to do, how that could affect clinical research pathways, and what practical implications may follow for access, oversight, and compliance. The piece is positioned as a microdosing focused policy update, linking the executive action to near-term expectations for the psychedelic industry and public conversation around potential therapeutic uses.